MMPI
FOLD

Morgenthaler Management Partners IX’s Amicus Therapeutics FOLD Stock Holding History

Morgenthaler Management Partners IX’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-1,783,948
Closed -$15.1M – 2
2016
Q1 		$15.1M Hold
1,783,948
– – 21.98% 2
2015
Q4 		$17.3M Buy
+1,783,948
New +$16.1M 18.83% 2

Other funds holding FOLD

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return

Morgenthaler Management Partners IX's FOLD Position: Q2 2016 in Review

Morgenthaler Management Partners IX sold out of Amicus Therapeutics (FOLD) in Q2 2016, closing a stake of 1,783,948 shares — an estimated $15.1M sold.

Morgenthaler Management Partners IX first reported a position in FOLD in Q4 2015 and held it in 2 quarters. The position peaked at $17.3M in Q4 2015. 130 funds tracked by Wall St. Rank hold FOLD as of Q2 2016.

  • Morgenthaler Management Partners IX reported no remaining Amicus Therapeutics position as of Q2 2016 after selling out during the quarter.
  • Morgenthaler Management Partners IX sold 1,783,948 Amicus Therapeutics shares in Q2 2016, an estimated $15.1M.
  • Morgenthaler Management Partners IX first reported a position in Amicus Therapeutics in Q4 2015 and held it in 2 quarters.
  • Morgenthaler Management Partners IX's Amicus Therapeutics position peaked at $17.3M in Q4 2015.
  • 130 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q2 2016.

Based on Morgenthaler Management Partners IX's 13F filing for Q2 2016, filed 4 Aug 2016.